{:	data{$I"/:ET{:default{	:	lastI"3+<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette </title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle"></span></h1>
			<!-- title block :: end -->
 
<!-- title block :: begin -->
<img class="photo" src="jeff.jpg" alt="Photo of Jeff">

<p class="geo">Brown University<br>
	Warren Alpert Medical School<br>
	Class of 2013
</p>
<p class="geo">
	jeffrey_guenette &#43; &#64;brown &#43; .edu<br>
	<a href="http://jpguenette.github.io">jpguenette.github.io</a>
</p>
<p class="geo">
	<a href="GuenetteJP_CV.pdf">Current CV</a> (download as PDF)
</p>
<!-- title block :: end -->

<!-- bio block :: begin -->
<p class="bio" id="first">
	I am a fourth-year medical student at <a href="http://www.brown.edu/academics/medical/" target="brown">Brown University</a>. 
	In June 2013 I will begin an internship in Internal Medicine at <a href="http://www.mountauburnhospital.org" target="auburn">
	Mount Auburn Hospital</a> and in July 2014 I will begin a Radiology residency at 
	<a href="http://www.brighamandwomens.org" target="brigham">Brigham &#38; Women's Hospital</a>. I will also hold a Clinical 
	Fellow appointment at <a href="http://www.harvard.edu" target="harvard">Harvard University</a>.
</p>
<p class="bio">
	Throughout medical school I have conducted clinical research with 
	<a href="http://biomed.brown.edu/facultydirectory/profile.php?id=1100924038" target="dupuy">Damian Dupuy</a>, studying 
	outcomes of and imaging features associated with percutaneous image-guided tumor ablation. I am interested in minimizing 
	medical treatment morbidity, medical waste, and medical costs. I am also fascinated by: human and computer vision; human 
	morphology; and human evolutionary biology, particularly related to the gut.
</p>
<p class="bio">
	Prior to medical school I worked in New York City at <a href="http://www.crystalco.com" target="crystal">Crystal &#38; 
	Company</a> for over five years as a business analyst. I graduated from 
	<a href="http://www.dartmouth.edu" target="dartmouth">Dartmouth College</a> with a BA in ancient history and completed a 
	postbac at <a href="http://gs.columbia.edu/postbac/" target="columbia"> Columbia University</a>.
</p>
<p class="bio">
	I am on <a href="https://twitter.com/gunetty" target="twitter">Twitter</a> and 
	<a href="http://www.linkedin.com/in/jpguenette" target="linkedin">LinkedIn</a> and I am married to 
	<a href="http://www.margaritamartinez.com" target="margarita">Margarita Martinez</a>, an actor, TV host, and singer-songwriter.
</p>
<!-- bio block :: end -->

<!-- CV :: begin -->
<h2>Scientific Publications</h2>
<img class="thumb" src="thumbs/JSO2010CHM.jpg" alt="CHM Ablation Image">
<p class="cv">
	<a href="publications/JSO2010CHM.html">Radiofrequency ablation of colorectal hepatic metastases</a><br>
	Guenette JP, Dupuy DE<br>
	J Surg Oncol. 2010;102(8):978-87
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/JVIR2013thyroid.jpg" alt="Thyroid Ablation Image">
<p class="cv"><a href="publications/JVIR2013Thyroid.html">Image-guided Ablation of Postsurgical Locoregional 
	Recurrence of Biopsy-proven Well-differentiated 
	Thyroid Carcinoma</a><br> 
	Guenette JP, Monchik JM, Dupuy DE<br>
	J Vasc Interv Radiol. 2013 May;24(5):672-9
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/Radiology2013bonemets.jpg" alt="Bone Ablation Image">
<p class="cv"><a href="publications/Radiology2013Bone.html">Solitary Painful Osseous Metastases: Correlation of 
	Imaging-Features with Pain Palliation after Radiofrequency Ablation &#45; A Multicenter American College of Radiology 
	Imaging Network Study</a><br>
	Guenette JP, Lopez MJ, Kim E, Dupuy DE<br>
	Radiology. In Press.
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/IGI2013lung.jpg" alt="Lung Ablation Image">
<p class="cv"><a href="publications/IGI2013Lung.html">Lung Ablation</a><br>
	Guenette JP, Dupuy DE in Mauro et. al., ed.<br>
	Image Guided Interventions 2/e<br>
	Elsevier. In Press.
</p>
<div class="clear"></div>

<h2>Scientific Abstracts</h2>
<img class="thumb" src="thumbs/JVIR2013thyroid.jpg" alt="Thyroid Ablation Image">
<p class="cv"><a href="abstracts/NESS2011Thyroid.html">Percutaneous Radiofrequency and Alcohol Ablation of Locally 
	Recurrent Well-Differentiated Thyroid Cancer</a><br>
	Guenette JP, Monchik JM, Dupuy DE<br>
	New England Surgical Society 92nd Annual Meeting<br>
	September 23-25, 2011, Bretton Woods, NH
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/Radiology2013bonemets.jpg" alt="Bone Ablation Image">
<p class="cv"><a href="abstracts/RSNA2011Bone.html">CT-guided Percutaneous Radiofrequency Ablation of Painful Bone 
	Metastases</a><br>
	Guenette JP, Hanna L, Ahrar K, Lopez-Ben RR, Dupuy DE<br>
	Radiological Society of North America 97th Scientific Assembly and National Meeting<br>
	December 1, 2011, Chicago, IL
</p>
<div class="clear"></div>

<h2>Scientific &#38; Educational Exhibits</h2>
<img class="thumb" src="thumbs/AAES2012thyroid.jpg" alt="Poster Thumbnail">
<p class="cv"><a href="exhibits/AAES2012Thyroid.html">Image-Guided Ablation of Local Recurrent and Distant Metastatic 
	Well-Differentiated Thyroid Cancer</a><br>
	Guenette JP, Monchik JM, Dupuy DE<br>
	American Association of Endocrine Surgeons Annual Meeting<br>
	April 29-May 1, 2012, Iowa City, IA
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/RSNA2012extracrani.jpg" alt="Poster Thumbnail">
<p class="cv"><a href="exhibits/RSNA2012ExtraCrani.html">Extracranial Tumors of the Head and Neck: Palliative and Curative 
	Roles for Image-Guided Ablation</a><br>
	Guenette JP, Monchik JM, Dupuy DE<br>
	Radiological Society of North America 98th Scientific Assembly and National Meeting<br>
	November 25-30, 2012, Chicago, IL
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/RSNA2012modalities.jpg" alt="Poster Thumbnail">
<p class="cv"><a href="exhibits/RSNA2012Modalities.html">A Guide to Choosing the Best Thermal Ablation Modality When Treating 
	Soft Tissue Tumors</a><br>
	Guenette JP, Mayo-Smith WW, Healey TT, Iannuccilli JD, Dupuy DE<br>
	Radiological Society of North America 98th Scientific Assembly and National Meeting<br>
	November 25-30, 2012, Chicago, IL<br>
	Awarded: Certificate of Merit
</p>
<div class="clear"></div>
<!-- CV :: end -->

<!-- interesting links :: start -->
<h2>Thoughtful &#38; Provocative Links</h2>

<p class="begin">The best statistics/public health presentation you will ever see: 
	<a href="http://www.ted.com/talks/hans_rosling_shows_the_best_stats_you_ve_ever_seen.html" target="link1">Hans Rosling 
		&#64; TED</a></p>
<p>Why too many medical tests is a bad thing: 
	<a href="http://www.nytimes.com/2009/12/13/magazine/13Fob-wwln-t.html" target="link2">Mammogram Math &#64; NY Times</a></p>
<p>Why biased research is a bad thing: 
	<a href="http://www.theatlantic.com/magazine/archive/2010/11/lies-damned-lies-and-medical-science/8269/" target="link3">
	Lies, Damned Lies, and Medical Science &#64; The Atlantic</a></p>
<p>Why to take meds only when necessary: 
		<a href="http://www.treehugger.com/corporate-responsibility/resistance-antibiotics-now-kills-more-people-aids.html" 
		target="link9">Resistance to antibiotics now kills more people than AIDS &#64; TreeHugger</a></p>
<p>The MMR vaccine does NOT cause autism: <a href="http://tallguywrites.livejournal.com/148012.html" target="link7">The Facts 
	In The Case of Dr. Andrew Wakefield &#64; TallGuyWrites</a></p>
<p>Why high-fructose corn syrup is horrible for you: <a href="http://www.youtube.com/watch?v=dBnniua6-oM" target="link11">
	Sugar: The Bitter Truth &#64; YouTube</a></p>
<p>Pesticides may affect your brain (in addition to the environment):
	<a href="http://www.reuters.com/article/idUSTRE67N4X920100824" target="link5">Pesticides Linked to Attention Problems 
	&#64; Reuters</a></p>
<p>Climate change exists and you should care: 
	<a href="http://www.wired.com/wiredscience/2009/12/climate-psychology/" target="link4">Psychology of Climate Change 
	&#64; Wired</a></p>
<p>Why we should stop being so wasteful: <a href="http://www.storyofstuff.org/movies-all/story-of-stuff/" target="link6">
	Story of Stuff</a></p>
<p>The 2nd Amendment was for militias: <a href="http://www.pbs.org/wgbh/pages/frontline/government-elections-politics/how-conservatives-reinvented-the-second-amendment/" 
		target="link8">How Conservatives ‚ÄúReinvented‚Äù the Second Amendment &#64; PBS/Frontline</a></p>
<p>Awesome rumination on thinking and running: <a href="http://edge.org/conversation/-brains-plus-brawn" target="link10">
	Brains Plus Brawn &#64; edge.com</a></p>
<p>We can manipulate atoms!
	<a href="http://www.latimes.com/news/science/sciencenow/la-sci-sn-ibm-world-smallest-movie-atoms-20130501,0,5172409.story" 
	target="link7">A Boy And His Atom &#64; LA Times</a></p>
<!-- interesting links :: end -->

<!-- friends links :: start -->
<h2>Artistic Friends Doing Cool Work</h2>
<p class="begin">Margarita Martinez (my wife), actor and singer/songwriter: 
	<a href="http://www.margaritamartinez.com" target="margarita">www.margaritamartinez.com</a></p>
<p>Leah Bonvissuto, theater director: 
	<a href="http://www.leahbonvissuto.com" target="leah">www.leahbonvissuto.com</a></p>
<p>Tatiana Gomberg, actor: <a href="http://www.tatianagomberg.com" target="tatiana">www.tatianagomberg.com</a></p>
<p>Hannah Kasper, painter: <a href="http://www.hannahkasper.com" target="hannah">www.hannahkasper.com</a></p>
<p>Stephen Levinson, writer: <a href="http://www.stephenlevinson.com" target="stephen">www.stephenlevinson.com</a></p>
<p>Timothy McDonough, actor: 
	<a href="http://www.timothyjohnmcdonough.com" target="tim">www.timothyjohnmcdonough.com</a></p>
<p>Hyunch Sung, installation artist/landscape architect: 
	<a href="http://www.hyunchoosung.com" target="hyunch">www.hyunchoosung.com</a></p>
<p>Hannah Volfson, graphic designer: 
	<a href="http://www.hannahvolfson.com" target="hannah">www.hannahvolfson.com</a></p>
<!-- friends links :: end -->
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T:rawI"U&<!-- title block :: begin -->
<img class="photo" src="jeff.jpg" alt="Photo of Jeff">

<p class="geo">Brown University<br>
	Warren Alpert Medical School<br>
	Class of 2013
</p>
<p class="geo">
	jeffrey_guenette &#43; &#64;brown &#43; .edu<br>
	<a href="http://jpguenette.github.io">jpguenette.github.io</a>
</p>
<p class="geo">
	<a href="GuenetteJP_CV.pdf">Current CV</a> (download as PDF)
</p>
<!-- title block :: end -->

<!-- bio block :: begin -->
<p class="bio" id="first">
	I am a fourth-year medical student at <a href="http://www.brown.edu/academics/medical/" target="brown">Brown University</a>. 
	In June 2013 I will begin an internship in Internal Medicine at <a href="http://www.mountauburnhospital.org" target="auburn">
	Mount Auburn Hospital</a> and in July 2014 I will begin a Radiology residency at 
	<a href="http://www.brighamandwomens.org" target="brigham">Brigham &#38; Women's Hospital</a>. I will also hold a Clinical 
	Fellow appointment at <a href="http://www.harvard.edu" target="harvard">Harvard University</a>.
</p>
<p class="bio">
	Throughout medical school I have conducted clinical research with 
	<a href="http://biomed.brown.edu/facultydirectory/profile.php?id=1100924038" target="dupuy">Damian Dupuy</a>, studying 
	outcomes of and imaging features associated with percutaneous image-guided tumor ablation. I am interested in minimizing 
	medical treatment morbidity, medical waste, and medical costs. I am also fascinated by: human and computer vision; human 
	morphology; and human evolutionary biology, particularly related to the gut.
</p>
<p class="bio">
	Prior to medical school I worked in New York City at <a href="http://www.crystalco.com" target="crystal">Crystal &#38; 
	Company</a> for over five years as a business analyst. I graduated from 
	<a href="http://www.dartmouth.edu" target="dartmouth">Dartmouth College</a> with a BA in ancient history and completed a 
	postbac at <a href="http://gs.columbia.edu/postbac/" target="columbia"> Columbia University</a>.
</p>
<p class="bio">
	I am on <a href="https://twitter.com/gunetty" target="twitter">Twitter</a> and 
	<a href="http://www.linkedin.com/in/jpguenette" target="linkedin">LinkedIn</a> and I am married to 
	<a href="http://www.margaritamartinez.com" target="margarita">Margarita Martinez</a>, an actor, TV host, and singer-songwriter.
</p>
<!-- bio block :: end -->

<!-- CV :: begin -->
<h2>Scientific Publications</h2>
<img class="thumb" src="thumbs/JSO2010CHM.jpg" alt="CHM Ablation Image">
<p class="cv">
	<a href="publications/JSO2010CHM.html">Radiofrequency ablation of colorectal hepatic metastases</a><br>
	Guenette JP, Dupuy DE<br>
	J Surg Oncol. 2010;102(8):978-87
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/JVIR2013thyroid.jpg" alt="Thyroid Ablation Image">
<p class="cv"><a href="publications/JVIR2013Thyroid.html">Image-guided Ablation of Postsurgical Locoregional 
	Recurrence of Biopsy-proven Well-differentiated 
	Thyroid Carcinoma</a><br> 
	Guenette JP, Monchik JM, Dupuy DE<br>
	J Vasc Interv Radiol. 2013 May;24(5):672-9
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/Radiology2013bonemets.jpg" alt="Bone Ablation Image">
<p class="cv"><a href="publications/Radiology2013Bone.html">Solitary Painful Osseous Metastases: Correlation of 
	Imaging-Features with Pain Palliation after Radiofrequency Ablation &#45; A Multicenter American College of Radiology 
	Imaging Network Study</a><br>
	Guenette JP, Lopez MJ, Kim E, Dupuy DE<br>
	Radiology. In Press.
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/IGI2013lung.jpg" alt="Lung Ablation Image">
<p class="cv"><a href="publications/IGI2013Lung.html">Lung Ablation</a><br>
	Guenette JP, Dupuy DE in Mauro et. al., ed.<br>
	Image Guided Interventions 2/e<br>
	Elsevier. In Press.
</p>
<div class="clear"></div>

<h2>Scientific Abstracts</h2>
<img class="thumb" src="thumbs/JVIR2013thyroid.jpg" alt="Thyroid Ablation Image">
<p class="cv"><a href="abstracts/NESS2011Thyroid.html">Percutaneous Radiofrequency and Alcohol Ablation of Locally 
	Recurrent Well-Differentiated Thyroid Cancer</a><br>
	Guenette JP, Monchik JM, Dupuy DE<br>
	New England Surgical Society 92nd Annual Meeting<br>
	September 23-25, 2011, Bretton Woods, NH
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/Radiology2013bonemets.jpg" alt="Bone Ablation Image">
<p class="cv"><a href="abstracts/RSNA2011Bone.html">CT-guided Percutaneous Radiofrequency Ablation of Painful Bone 
	Metastases</a><br>
	Guenette JP, Hanna L, Ahrar K, Lopez-Ben RR, Dupuy DE<br>
	Radiological Society of North America 97th Scientific Assembly and National Meeting<br>
	December 1, 2011, Chicago, IL
</p>
<div class="clear"></div>

<h2>Scientific &#38; Educational Exhibits</h2>
<img class="thumb" src="thumbs/AAES2012thyroid.jpg" alt="Poster Thumbnail">
<p class="cv"><a href="exhibits/AAES2012Thyroid.html">Image-Guided Ablation of Local Recurrent and Distant Metastatic 
	Well-Differentiated Thyroid Cancer</a><br>
	Guenette JP, Monchik JM, Dupuy DE<br>
	American Association of Endocrine Surgeons Annual Meeting<br>
	April 29-May 1, 2012, Iowa City, IA
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/RSNA2012extracrani.jpg" alt="Poster Thumbnail">
<p class="cv"><a href="exhibits/RSNA2012ExtraCrani.html">Extracranial Tumors of the Head and Neck: Palliative and Curative 
	Roles for Image-Guided Ablation</a><br>
	Guenette JP, Monchik JM, Dupuy DE<br>
	Radiological Society of North America 98th Scientific Assembly and National Meeting<br>
	November 25-30, 2012, Chicago, IL
</p>
<div class="clear"></div>
<img class="thumb" src="thumbs/RSNA2012modalities.jpg" alt="Poster Thumbnail">
<p class="cv"><a href="exhibits/RSNA2012Modalities.html">A Guide to Choosing the Best Thermal Ablation Modality When Treating 
	Soft Tissue Tumors</a><br>
	Guenette JP, Mayo-Smith WW, Healey TT, Iannuccilli JD, Dupuy DE<br>
	Radiological Society of North America 98th Scientific Assembly and National Meeting<br>
	November 25-30, 2012, Chicago, IL<br>
	Awarded: Certificate of Merit
</p>
<div class="clear"></div>
<!-- CV :: end -->

<!-- interesting links :: start -->
<h2>Thoughtful &#38; Provocative Links</h2>

<p class="begin">The best statistics/public health presentation you will ever see: 
	<a href="http://www.ted.com/talks/hans_rosling_shows_the_best_stats_you_ve_ever_seen.html" target="link1">Hans Rosling 
		&#64; TED</a></p>
<p>Why too many medical tests is a bad thing: 
	<a href="http://www.nytimes.com/2009/12/13/magazine/13Fob-wwln-t.html" target="link2">Mammogram Math &#64; NY Times</a></p>
<p>Why biased research is a bad thing: 
	<a href="http://www.theatlantic.com/magazine/archive/2010/11/lies-damned-lies-and-medical-science/8269/" target="link3">
	Lies, Damned Lies, and Medical Science &#64; The Atlantic</a></p>
<p>Why to take meds only when necessary: 
		<a href="http://www.treehugger.com/corporate-responsibility/resistance-antibiotics-now-kills-more-people-aids.html" 
		target="link9">Resistance to antibiotics now kills more people than AIDS &#64; TreeHugger</a></p>
<p>The MMR vaccine does NOT cause autism: <a href="http://tallguywrites.livejournal.com/148012.html" target="link7">The Facts 
	In The Case of Dr. Andrew Wakefield &#64; TallGuyWrites</a></p>
<p>Why high-fructose corn syrup is horrible for you: <a href="http://www.youtube.com/watch?v=dBnniua6-oM" target="link11">
	Sugar: The Bitter Truth &#64; YouTube</a></p>
<p>Pesticides may affect your brain (in addition to the environment):
	<a href="http://www.reuters.com/article/idUSTRE67N4X920100824" target="link5">Pesticides Linked to Attention Problems 
	&#64; Reuters</a></p>
<p>Climate change exists and you should care: 
	<a href="http://www.wired.com/wiredscience/2009/12/climate-psychology/" target="link4">Psychology of Climate Change 
	&#64; Wired</a></p>
<p>Why we should stop being so wasteful: <a href="http://www.storyofstuff.org/movies-all/story-of-stuff/" target="link6">
	Story of Stuff</a></p>
<p>The 2nd Amendment was for militias: <a href="http://www.pbs.org/wgbh/pages/frontline/government-elections-politics/how-conservatives-reinvented-the-second-amendment/" 
		target="link8">How Conservatives ‚ÄúReinvented‚Äù the Second Amendment &#64; PBS/Frontline</a></p>
<p>Awesome rumination on thinking and running: <a href="http://edge.org/conversation/-brains-plus-brawn" target="link10">
	Brains Plus Brawn &#64; edge.com</a></p>
<p>We can manipulate atoms!
	<a href="http://www.latimes.com/news/science/sciencenow/la-sci-sn-ibm-world-smallest-movie-atoms-20130501,0,5172409.story" 
	target="link7">A Boy And His Atom &#64; LA Times</a></p>
<!-- interesting links :: end -->

<!-- friends links :: start -->
<h2>Artistic Friends Doing Cool Work</h2>
<p class="begin">Margarita Martinez (my wife), actor and singer/songwriter: 
	<a href="http://www.margaritamartinez.com" target="margarita">www.margaritamartinez.com</a></p>
<p>Leah Bonvissuto, theater director: 
	<a href="http://www.leahbonvissuto.com" target="leah">www.leahbonvissuto.com</a></p>
<p>Tatiana Gomberg, actor: <a href="http://www.tatianagomberg.com" target="tatiana">www.tatianagomberg.com</a></p>
<p>Hannah Kasper, painter: <a href="http://www.hannahkasper.com" target="hannah">www.hannahkasper.com</a></p>
<p>Stephen Levinson, writer: <a href="http://www.stephenlevinson.com" target="stephen">www.stephenlevinson.com</a></p>
<p>Timothy McDonough, actor: 
	<a href="http://www.timothyjohnmcdonough.com" target="tim">www.timothyjohnmcdonough.com</a></p>
<p>Hyunch Sung, installation artist/landscape architect: 
	<a href="http://www.hyunchoosung.com" target="hyunch">www.hyunchoosung.com</a></p>
<p>Hannah Volfson, graphic designer: 
	<a href="http://www.hannahvolfson.com" target="hannah">www.hannahvolfson.com</a></p>
<!-- friends links :: end -->;T:pre@:	post@
I"/stylesheet/;T{;{;I"Èbody {
	background: #446644;
	margin: 80px 0 0 0;
	padding: 0px;
	text-align: center;
}

a, a:visited {
	color:#CC9900;
}

a:hover {
	color:#997700;
}

#container {
	width: 900px;
	margin: 0px auto;
	text-align: left;
	font-family: Helvetica, Verdana, Arial, sans-serif;
	color: #DDDDDD;
	font-size: 16px;
	line-height: 1.2em;
}

h1 {
	color: #FFFFFF;
	font-size: 36px;
	font-weight: bold;
}

h2 {
	border-top: 1px solid black;
	color: #FFFFFF;
	font-size: 22px;
	font-weight: bold;
	margin: 20px 0 0 0;	
	padding: 30px 0 0 0;
	line-height: 1.3em;
	clear: both;
}

h3 {
	border-top: 1px solid black;
	color: #CC9900;
	font-size: 22px;
	font-weight: bold;
	margin: 20px 0 0 0;	
	padding: 30px 0 5px 0;
	line-height: 1.3em;
	clear: both;
}

h4 {
	color: #FFFFFF;
	font-size: 18px;
	font-weight: bold;
	margin: 20px 0 0 0;	
}

p {
	margin: 0 0 0 0;
	overflow: hidden;
}

p.geo {
	margin: 10px 0 0 0;
	font-size: 14px;
}

p.bio {
	margin: 20px 0 0 0;
}

p.cv {
	font-size: 14px;
	margin: 20px 0 0 0;
}

p.begin {
	margin: 10px 0 0 0;
}

p.return {
	margin: 20px 0 0 0;
}

#first {
	margin: 35px 0 0 0;
}

img.photo {
	float: right;
	position: relative;
	margin: 5px 0 0 0;
}

img.thumb {
	float: left;
	position: relative;
	margin: 20px 15px 0 0;
}

img.abstractImage {
	float: left;
	position: relative;
	margin-right: 15px;
}

span.subtitle {
	color: #DDDDDD;
	font-size: 28px;
}

.clear { 
	clear: both;
}

.footer {
	padding: 15px 0 30px 0;
	margin: 25px 0 0 0;
	border-top: 1px solid black;
	text-align:center;
};T;	@;
@I"/jeff/;T{;{ I"/thumbs/AAES2012thyroid/;T{;{ I"/thumbs/IGI2013lung/;T{;{ I"/thumbs/JSO2010CHM/;T{;{ I"/thumbs/JVIR2013thyroid/;T{;{ I"#/thumbs/Radiology2013bonemets/;T{;{ I" /thumbs/RSNA2012extracrani/;T{;{ I" /thumbs/RSNA2012modalities/;T{;{ I"/ruby_logo/;T{;{ I"/JSO2010CHM/;T{;{	;I"N	<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Publications</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Publications</span></h1>
			<!-- title block :: end -->
 
<h3>Radiofrequency ablation of colorectal hepatic metastases</h3>

<p class="mainContent_abstractData">
	Guenette JP, Dupuy DE
	<br>J Surg Oncol. 2010;102(8):978-87
	<br>Publication Access via <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21166002" target="pubmed">PubMed</a>
	
	
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/thyroid375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous 
approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should 
be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general 
anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further 
increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"@Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous 
approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should 
be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general 
anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further 
increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.;T;
I"@Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous 
approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should 
be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general 
anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further 
increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.;T;@.I"/largeimages/thyroid375/;T{;{ I"/publications/JSO2010CHM/;T{;{	;I"Q	<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Publications</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Publications</span></h1>
			<!-- title block :: end -->
 
<h3>Radiofrequency ablation of colorectal hepatic metastases</h3>

<p class="mainContent_abstractData">
	Guenette JP, Dupuy DE
	<br>J Surg Oncol. 2010;102(8):978-87
	<br>Publication Access via <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21166002" target="pubmed">PubMed</a>
	
	
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/JSO2010CHM375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous 
approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should 
be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general 
anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further 
increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"@Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous 
approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should 
be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general 
anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further 
increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.;T;
I"@Radiofrequency ablation (RFA) may be performed intraoperatively, laparoscopically, or percutaneously. The percutaneous 
approach is associated with the least procedural risk and may be performed under local anesthesia. Percutaneous RFA should 
be considered a primary treatment option for patients with unresectable hepatic tumors or conditions that prohibit general 
anesthesia or abdominal surgery. Continually improving thermal ablation and imaging technologies are likely to further 
increase tumor ablation efficacy and expand its role in treatment of hepatic metastases.;T;@7I"#/publications/JVIR2013Thyroid/;T{;{	;I"≤<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Publications</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Publications</span></h1>
			<!-- title block :: end -->
 
<h3>Image-guided Ablation of Postsurgical Locoregional Recurrence of Biopsy-proven Well-differentiated Thyroid Carcinoma</h3>

<p class="mainContent_abstractData">
	Guenette JP, Monchik JM, Dupuy DE
	<br>J Vasc Interv Radiol. 2013 May;24(5):672-9
	<br>Publication Access via <a href="http://www.ncbi.nlm.nih.gov/pubmed/23622038" target="pubmed">PubMed</a>
	
	
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/JVIR2013thyroid375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	PURPOSE: To evaluate the clinical outcomes of ultrasound-guided percutaneous radiofrequency (RF) ablation and percutaneous ethanol injection (PEI) as salvage therapy for locoregional recurrence after resection of well-differentiated thyroid carcinoma.<br><br>

MATERIALS AND METHODS: There were 42 locoregional, biopsy-proven, papillary and follicular thyroid carcinoma lesions (0.5-3.7 cm) treated, 21 with RF ablation and 21 with PEI. Of treated lesions, 35 were located in the lateral compartments, and 7 were located in the central compartment. Data points in the retrospective analysis, determined beforehand by the investigators, were progression at the ablation site, serum thyroglobulin levels before and after the procedure, and procedural complications.<br><br>

RESULTS: Average follow-up after RF ablation was 61.3 months and after PEI was 38.5 months. No progression was detected in the region of ablation for any of the lesions treated with RF ablation. Local progression was detected 4-11 months after ablation in 5 of the 21 lesions treated with PEI, 3 in the lateral compartment and 2 in the central compartment; all of the lesions were successfully retreated with repeat PEI, RF ablation, or surgery. Permanent vocal cord paralysis occurred after one RF ablation procedure of a lateral compartment supraclavicular node. There were no complications after PEI.<br><br>

CONCLUSIONS: This case series provides long-term follow-up evidence of the safety and efficacy of ultrasound-guided RF ablation and PEI for control of locoregional recurrence of well-differentiated thyroid carcinoma after surgery.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"PPURPOSE: To evaluate the clinical outcomes of ultrasound-guided percutaneous radiofrequency (RF) ablation and percutaneous ethanol injection (PEI) as salvage therapy for locoregional recurrence after resection of well-differentiated thyroid carcinoma.<br><br>

MATERIALS AND METHODS: There were 42 locoregional, biopsy-proven, papillary and follicular thyroid carcinoma lesions (0.5-3.7 cm) treated, 21 with RF ablation and 21 with PEI. Of treated lesions, 35 were located in the lateral compartments, and 7 were located in the central compartment. Data points in the retrospective analysis, determined beforehand by the investigators, were progression at the ablation site, serum thyroglobulin levels before and after the procedure, and procedural complications.<br><br>

RESULTS: Average follow-up after RF ablation was 61.3 months and after PEI was 38.5 months. No progression was detected in the region of ablation for any of the lesions treated with RF ablation. Local progression was detected 4-11 months after ablation in 5 of the 21 lesions treated with PEI, 3 in the lateral compartment and 2 in the central compartment; all of the lesions were successfully retreated with repeat PEI, RF ablation, or surgery. Permanent vocal cord paralysis occurred after one RF ablation procedure of a lateral compartment supraclavicular node. There were no complications after PEI.<br><br>

CONCLUSIONS: This case series provides long-term follow-up evidence of the safety and efficacy of ultrasound-guided RF ablation and PEI for control of locoregional recurrence of well-differentiated thyroid carcinoma after surgery.;T;
I"PPURPOSE: To evaluate the clinical outcomes of ultrasound-guided percutaneous radiofrequency (RF) ablation and percutaneous ethanol injection (PEI) as salvage therapy for locoregional recurrence after resection of well-differentiated thyroid carcinoma.<br><br>

MATERIALS AND METHODS: There were 42 locoregional, biopsy-proven, papillary and follicular thyroid carcinoma lesions (0.5-3.7 cm) treated, 21 with RF ablation and 21 with PEI. Of treated lesions, 35 were located in the lateral compartments, and 7 were located in the central compartment. Data points in the retrospective analysis, determined beforehand by the investigators, were progression at the ablation site, serum thyroglobulin levels before and after the procedure, and procedural complications.<br><br>

RESULTS: Average follow-up after RF ablation was 61.3 months and after PEI was 38.5 months. No progression was detected in the region of ablation for any of the lesions treated with RF ablation. Local progression was detected 4-11 months after ablation in 5 of the 21 lesions treated with PEI, 3 in the lateral compartment and 2 in the central compartment; all of the lesions were successfully retreated with repeat PEI, RF ablation, or surgery. Permanent vocal cord paralysis occurred after one RF ablation procedure of a lateral compartment supraclavicular node. There were no complications after PEI.<br><br>

CONCLUSIONS: This case series provides long-term follow-up evidence of the safety and efficacy of ultrasound-guided RF ablation and PEI for control of locoregional recurrence of well-differentiated thyroid carcinoma after surgery.;T;@=I" /abstracts/NESS2011Thyroid/;T{;{	;I"<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Abstracts</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Abstracts</span></h1>
			<!-- title block :: end -->
 
<h3>Percutaneous Radiofrequency and Alcohol Ablation of Locally Recurrent Well-Differentiated Thyroid Cancer</h3>

<p class="mainContent_abstractData">
	Guenette JP, Monchik JM, Dupuy DE
	
	
	<br>New England Surgical Society 92nd Annual Meeting
	<br>September 23-25, 2011, Bretton Woods, NH
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/JVIR2013thyroid375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	OBJECTIVE: Assess the long-term outcomes of radiofrequency ablation (RFA) and alcohol ablation (EtOH) of local recurrences of well-differentiated thyroid cancer (WTC) following adequate surgery.<br><br>

DESIGN: Retrospective cohort. Mean follow-up 51.5 months.<br><br>

SETTING: Tertiary care center.<br><br>

PATIENTS: Forty-two WTC lesions were treated in 23 patients from 1998 to 2010. Thirty-five lateral compartment lesions were treated, 19 with RFA, 16 with EtOH. Seven central compartment lesions were treated, 2 with RFA, 5 with EtOH. Patients with lateral compartment recurrences previously had modified neck dissection. Patients with central compartment recurrences previously had total thyroidectomy and careful central compartment node exploration and/or dissection. A single experienced endocrine surgeon performed all pre-ablation surgery.<br><br>

INTERVENTIONS: Percutaneous CT-guided radiofrequency ablation and ultrasound-guided 100% ethanol injection.<br><br>

MAIN OUTCOME MEASURE: Tumor recurrence, pre- and post-operative serum thyroglobulin (Tg), and procedural complications. Patients were followed with routine US, 131I whole body scan, and/or serum Tg levels.<br><br>

RESULTS: No recurrent disease was detected in any of the 21 lesions treated with RFA (average:1.5cm; range: 0.5-3.7cm). Recurrent disease was detected in 5 of the 21 lesions treated with EtOH (average: 1.1cm; range: 0.5-1.5cm). One lateral compartment recurrence was successfully treated with RFA, two others were successfully retreated with EtOH. Two central compartment recurrences required surgery. Permanent vocal cord paralysis occurred following one RFA procedure. Tg levels decreased to or remained at undetectable or low detectable levels following all 10 procedures for which both pre-ablation and post-ablation Tg levels were available with undetectable antibodies.<br><br>

CONCLUSION: Both RFA and EtOH are safe and feasible treatment options for local WTC recurrence following adequate initial surgery by an experienced endocrine surgeon.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"ˇOBJECTIVE: Assess the long-term outcomes of radiofrequency ablation (RFA) and alcohol ablation (EtOH) of local recurrences of well-differentiated thyroid cancer (WTC) following adequate surgery.<br><br>

DESIGN: Retrospective cohort. Mean follow-up 51.5 months.<br><br>

SETTING: Tertiary care center.<br><br>

PATIENTS: Forty-two WTC lesions were treated in 23 patients from 1998 to 2010. Thirty-five lateral compartment lesions were treated, 19 with RFA, 16 with EtOH. Seven central compartment lesions were treated, 2 with RFA, 5 with EtOH. Patients with lateral compartment recurrences previously had modified neck dissection. Patients with central compartment recurrences previously had total thyroidectomy and careful central compartment node exploration and/or dissection. A single experienced endocrine surgeon performed all pre-ablation surgery.<br><br>

INTERVENTIONS: Percutaneous CT-guided radiofrequency ablation and ultrasound-guided 100% ethanol injection.<br><br>

MAIN OUTCOME MEASURE: Tumor recurrence, pre- and post-operative serum thyroglobulin (Tg), and procedural complications. Patients were followed with routine US, 131I whole body scan, and/or serum Tg levels.<br><br>

RESULTS: No recurrent disease was detected in any of the 21 lesions treated with RFA (average:1.5cm; range: 0.5-3.7cm). Recurrent disease was detected in 5 of the 21 lesions treated with EtOH (average: 1.1cm; range: 0.5-1.5cm). One lateral compartment recurrence was successfully treated with RFA, two others were successfully retreated with EtOH. Two central compartment recurrences required surgery. Permanent vocal cord paralysis occurred following one RFA procedure. Tg levels decreased to or remained at undetectable or low detectable levels following all 10 procedures for which both pre-ablation and post-ablation Tg levels were available with undetectable antibodies.<br><br>

CONCLUSION: Both RFA and EtOH are safe and feasible treatment options for local WTC recurrence following adequate initial surgery by an experienced endocrine surgeon.;T;
I"ˇOBJECTIVE: Assess the long-term outcomes of radiofrequency ablation (RFA) and alcohol ablation (EtOH) of local recurrences of well-differentiated thyroid cancer (WTC) following adequate surgery.<br><br>

DESIGN: Retrospective cohort. Mean follow-up 51.5 months.<br><br>

SETTING: Tertiary care center.<br><br>

PATIENTS: Forty-two WTC lesions were treated in 23 patients from 1998 to 2010. Thirty-five lateral compartment lesions were treated, 19 with RFA, 16 with EtOH. Seven central compartment lesions were treated, 2 with RFA, 5 with EtOH. Patients with lateral compartment recurrences previously had modified neck dissection. Patients with central compartment recurrences previously had total thyroidectomy and careful central compartment node exploration and/or dissection. A single experienced endocrine surgeon performed all pre-ablation surgery.<br><br>

INTERVENTIONS: Percutaneous CT-guided radiofrequency ablation and ultrasound-guided 100% ethanol injection.<br><br>

MAIN OUTCOME MEASURE: Tumor recurrence, pre- and post-operative serum thyroglobulin (Tg), and procedural complications. Patients were followed with routine US, 131I whole body scan, and/or serum Tg levels.<br><br>

RESULTS: No recurrent disease was detected in any of the 21 lesions treated with RFA (average:1.5cm; range: 0.5-3.7cm). Recurrent disease was detected in 5 of the 21 lesions treated with EtOH (average: 1.1cm; range: 0.5-1.5cm). One lateral compartment recurrence was successfully treated with RFA, two others were successfully retreated with EtOH. Two central compartment recurrences required surgery. Permanent vocal cord paralysis occurred following one RFA procedure. Tg levels decreased to or remained at undetectable or low detectable levels following all 10 procedures for which both pre-ablation and post-ablation Tg levels were available with undetectable antibodies.<br><br>

CONCLUSION: Both RFA and EtOH are safe and feasible treatment options for local WTC recurrence following adequate initial surgery by an experienced endocrine surgeon.;T;@CI"/abstracts/RSNA2011Bone/;T{;{	;I"<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Abstracts</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Abstracts</span></h1>
			<!-- title block :: end -->
 
<h3>CT-guided Percutaneous Radiofrequency Ablation of Painful Bone Metastases</h3>

<p class="mainContent_abstractData">
	Guenette JP, Hanna L, Ahrar K, Lopez-Ben RR, Dupuy DE
	
	
	<br>Radiological Society of North America 97th Scientific Assembly and National Meeting
	<br>December 1, 2011, Chicago, IL
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/Radiology2013Bone375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	PURPOSE: To identify which initial and follow-up imaging features are associated with significant changes in patient pain, relief, and mood following palliative CT-guided radiofrequency ablation of solitary painful bone metastases.<br><br>

METHOD AND MATERIALS: As part of the ACRIN 6661 multicenter cooperative group trial, radiofrequency ablation was performed on bone lesions with clinical and imaging features of metastatic disease in 55 patients. The lesions were solitary, measured no more than 8cm, and were the source of persistent intractable pain despite active treatment with narcotics. Follow-up, contrast-enhanced CT and/or MRI were performed at 1 and 3 months. On pretreatment, 1 month, and 3 month follow-up images, the following were assessed: maximum tumor size in three planes, tumor volume, bone-tumor interface (BTI), distance to major neurovascular (NV) bundles within 2cm, pathological fracture. On the post treatment images the maximum ablation zone size, percent of tumor ablated, percent of BTI ablated, enhancing rim width and regularity, ablation into NV bundle, general tumor progression, and tumor progression at the BTI were assessed. Pain and patient mood were measured using a modified Memorial Pain Assessment Card (MPAC). Preliminary statistical
analysis was performed using a univariate regression analysis in which the change in score from pre-RFA to 1-month post-RFA for a particular dimension of the MPAC was modeled as a linear function of each variable measured individually.<br><br>

RESULTS: The distance to the nearest NV bundle for tumors !2cm from a major NV bundle significantly correlated with the effect of RFA on pain: post-RFA pain decreased 24% (95% CI: 3% to 44%) for each centimeter of tumor distance from the NV bundle. Additional correlations, including lower levels of reported pain following ablation of smaller tumors, are apparent but may not be statistically significant.<br><br>

CONCLUSION: RFA reduction of pain from bone metastases is more effective with increased distance between the tumor and nearby major neurovascular bundles when a tumor is within 2cm of a major NV bundle. Other parameters may correlate with efficacy. Further statistical analysis is required. Work funded by grants U01 CA079778 and U01 CA080098.<br><br>

CLINICAL RELEVANCE/APPLICATION: Identifying imaging features associated with radiofrequency ablation effects on bone metastasis pain is important to future patient selection and to expanded use of this modality in palliative care.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"›	PURPOSE: To identify which initial and follow-up imaging features are associated with significant changes in patient pain, relief, and mood following palliative CT-guided radiofrequency ablation of solitary painful bone metastases.<br><br>

METHOD AND MATERIALS: As part of the ACRIN 6661 multicenter cooperative group trial, radiofrequency ablation was performed on bone lesions with clinical and imaging features of metastatic disease in 55 patients. The lesions were solitary, measured no more than 8cm, and were the source of persistent intractable pain despite active treatment with narcotics. Follow-up, contrast-enhanced CT and/or MRI were performed at 1 and 3 months. On pretreatment, 1 month, and 3 month follow-up images, the following were assessed: maximum tumor size in three planes, tumor volume, bone-tumor interface (BTI), distance to major neurovascular (NV) bundles within 2cm, pathological fracture. On the post treatment images the maximum ablation zone size, percent of tumor ablated, percent of BTI ablated, enhancing rim width and regularity, ablation into NV bundle, general tumor progression, and tumor progression at the BTI were assessed. Pain and patient mood were measured using a modified Memorial Pain Assessment Card (MPAC). Preliminary statistical
analysis was performed using a univariate regression analysis in which the change in score from pre-RFA to 1-month post-RFA for a particular dimension of the MPAC was modeled as a linear function of each variable measured individually.<br><br>

RESULTS: The distance to the nearest NV bundle for tumors !2cm from a major NV bundle significantly correlated with the effect of RFA on pain: post-RFA pain decreased 24% (95% CI: 3% to 44%) for each centimeter of tumor distance from the NV bundle. Additional correlations, including lower levels of reported pain following ablation of smaller tumors, are apparent but may not be statistically significant.<br><br>

CONCLUSION: RFA reduction of pain from bone metastases is more effective with increased distance between the tumor and nearby major neurovascular bundles when a tumor is within 2cm of a major NV bundle. Other parameters may correlate with efficacy. Further statistical analysis is required. Work funded by grants U01 CA079778 and U01 CA080098.<br><br>

CLINICAL RELEVANCE/APPLICATION: Identifying imaging features associated with radiofrequency ablation effects on bone metastasis pain is important to future patient selection and to expanded use of this modality in palliative care.;T;
I"›	PURPOSE: To identify which initial and follow-up imaging features are associated with significant changes in patient pain, relief, and mood following palliative CT-guided radiofrequency ablation of solitary painful bone metastases.<br><br>

METHOD AND MATERIALS: As part of the ACRIN 6661 multicenter cooperative group trial, radiofrequency ablation was performed on bone lesions with clinical and imaging features of metastatic disease in 55 patients. The lesions were solitary, measured no more than 8cm, and were the source of persistent intractable pain despite active treatment with narcotics. Follow-up, contrast-enhanced CT and/or MRI were performed at 1 and 3 months. On pretreatment, 1 month, and 3 month follow-up images, the following were assessed: maximum tumor size in three planes, tumor volume, bone-tumor interface (BTI), distance to major neurovascular (NV) bundles within 2cm, pathological fracture. On the post treatment images the maximum ablation zone size, percent of tumor ablated, percent of BTI ablated, enhancing rim width and regularity, ablation into NV bundle, general tumor progression, and tumor progression at the BTI were assessed. Pain and patient mood were measured using a modified Memorial Pain Assessment Card (MPAC). Preliminary statistical
analysis was performed using a univariate regression analysis in which the change in score from pre-RFA to 1-month post-RFA for a particular dimension of the MPAC was modeled as a linear function of each variable measured individually.<br><br>

RESULTS: The distance to the nearest NV bundle for tumors !2cm from a major NV bundle significantly correlated with the effect of RFA on pain: post-RFA pain decreased 24% (95% CI: 3% to 44%) for each centimeter of tumor distance from the NV bundle. Additional correlations, including lower levels of reported pain following ablation of smaller tumors, are apparent but may not be statistically significant.<br><br>

CONCLUSION: RFA reduction of pain from bone metastases is more effective with increased distance between the tumor and nearby major neurovascular bundles when a tumor is within 2cm of a major NV bundle. Other parameters may correlate with efficacy. Further statistical analysis is required. Work funded by grants U01 CA079778 and U01 CA080098.<br><br>

CLINICAL RELEVANCE/APPLICATION: Identifying imaging features associated with radiofrequency ablation effects on bone metastasis pain is important to future patient selection and to expanded use of this modality in palliative care.;T;@II"/exhibits/AAES2012Thyroid/;T{;{	;I"<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific &#38; Educational Exhibits</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific &#38; Educational Exhibits</span></h1>
			<!-- title block :: end -->
 
<h3>Image-Guided Ablation of Local Recurrent and Distant Metastatic Well-Differentiated Thyroid Cancer</h3>

<p class="mainContent_abstractData">
	Guenette JP, Monchik JM, Dupuy DE
	
	
	<br>American Association of Endocrine Surgeons Annual Meeting
	<br>April 29-May 1, 2012, Iowa City, IA
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/AAES2012Thyroid375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	BACKGROUND: Local well-differentiated thyroid cancer (WTC) recurrences are often difficult to treat surgically and distant metastases may arise in difficult-to-treat locations. We report our long-term results using image-guided ablation as treatment for
recurrent and metastatic WTC.<br><br>

METHOD: Thirty-five recurrent WTC neck lateral compartment lesions were treated in 19 patients. Of the 35 lesions, 19 were treated with radiofrequency ablation (RFA), 16 with ethanol ablation (EtOH). All patients previously had modified neck dissection performed by a single experienced endocrine surgeon. Data points included tumor recurrence, pre- and post-operative serum thyroglobulin (Tg),
and procedural complications. Patients were followed with routine US or CT, 131I whole body scan, and/or serum Tg levels. Eleven distant focal metastases were treated in 8 patients. Two lesions were treated in the clavicle, sternum, and lung, while one lesion
was treated in the humerus, 7th rib, sacrum, liver, and kidney. Methods of treatment included RFA for 7 lesions, microwave ablation for 2, and cryoablation for 2. Data points included tumor recurrence at the ablation site and procedural complications.<br><br>

RESULTS: Mean follow-up for treatment of neck lesions was 47.6 months. No recurrent disease was detected in the 19 lesions treated with RFA (mean size: 1.6cm; range: 0.5-3.7cm). Recurrent disease was detected in 3 of the 16 lesions treated with EtOH (mean size:
1.1cm; range: 0.5-1.5cm). One of these recurrences was successfully treated with RFA, two were successfully retreated with EtOH. Permanent vocal cord paralysis occurred following one RFA procedure of a lateral compartment supraclavicular node. Tg levels
were available for 9 of the 19 patients treated with neck ablation. In these patients, Tg levels decreased to or remained at undetectable or low detectable levels following ablation. Two of the 11 distant focal metastases recurred and were successfully
retreated with RFA, the remainder showed no sign of recurrence or disease progression at the treatment site at last follow-up (mean: 29.5 months; range: 7-60 months) and there were no treatment complications of distant focal lesions.<br><br>

CONCLUSION: Image-guided ablation is a safe and feasible treatment option for locally recurrent WTC following adequate surgery as well as for distant focal WTC metastases. Our results suggest that RFA is more effective than EtOH for local neck lesions despite being used to treat larger lesions.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"‘	BACKGROUND: Local well-differentiated thyroid cancer (WTC) recurrences are often difficult to treat surgically and distant metastases may arise in difficult-to-treat locations. We report our long-term results using image-guided ablation as treatment for
recurrent and metastatic WTC.<br><br>

METHOD: Thirty-five recurrent WTC neck lateral compartment lesions were treated in 19 patients. Of the 35 lesions, 19 were treated with radiofrequency ablation (RFA), 16 with ethanol ablation (EtOH). All patients previously had modified neck dissection performed by a single experienced endocrine surgeon. Data points included tumor recurrence, pre- and post-operative serum thyroglobulin (Tg),
and procedural complications. Patients were followed with routine US or CT, 131I whole body scan, and/or serum Tg levels. Eleven distant focal metastases were treated in 8 patients. Two lesions were treated in the clavicle, sternum, and lung, while one lesion
was treated in the humerus, 7th rib, sacrum, liver, and kidney. Methods of treatment included RFA for 7 lesions, microwave ablation for 2, and cryoablation for 2. Data points included tumor recurrence at the ablation site and procedural complications.<br><br>

RESULTS: Mean follow-up for treatment of neck lesions was 47.6 months. No recurrent disease was detected in the 19 lesions treated with RFA (mean size: 1.6cm; range: 0.5-3.7cm). Recurrent disease was detected in 3 of the 16 lesions treated with EtOH (mean size:
1.1cm; range: 0.5-1.5cm). One of these recurrences was successfully treated with RFA, two were successfully retreated with EtOH. Permanent vocal cord paralysis occurred following one RFA procedure of a lateral compartment supraclavicular node. Tg levels
were available for 9 of the 19 patients treated with neck ablation. In these patients, Tg levels decreased to or remained at undetectable or low detectable levels following ablation. Two of the 11 distant focal metastases recurred and were successfully
retreated with RFA, the remainder showed no sign of recurrence or disease progression at the treatment site at last follow-up (mean: 29.5 months; range: 7-60 months) and there were no treatment complications of distant focal lesions.<br><br>

CONCLUSION: Image-guided ablation is a safe and feasible treatment option for locally recurrent WTC following adequate surgery as well as for distant focal WTC metastases. Our results suggest that RFA is more effective than EtOH for local neck lesions despite being used to treat larger lesions.;T;
I"‘	BACKGROUND: Local well-differentiated thyroid cancer (WTC) recurrences are often difficult to treat surgically and distant metastases may arise in difficult-to-treat locations. We report our long-term results using image-guided ablation as treatment for
recurrent and metastatic WTC.<br><br>

METHOD: Thirty-five recurrent WTC neck lateral compartment lesions were treated in 19 patients. Of the 35 lesions, 19 were treated with radiofrequency ablation (RFA), 16 with ethanol ablation (EtOH). All patients previously had modified neck dissection performed by a single experienced endocrine surgeon. Data points included tumor recurrence, pre- and post-operative serum thyroglobulin (Tg),
and procedural complications. Patients were followed with routine US or CT, 131I whole body scan, and/or serum Tg levels. Eleven distant focal metastases were treated in 8 patients. Two lesions were treated in the clavicle, sternum, and lung, while one lesion
was treated in the humerus, 7th rib, sacrum, liver, and kidney. Methods of treatment included RFA for 7 lesions, microwave ablation for 2, and cryoablation for 2. Data points included tumor recurrence at the ablation site and procedural complications.<br><br>

RESULTS: Mean follow-up for treatment of neck lesions was 47.6 months. No recurrent disease was detected in the 19 lesions treated with RFA (mean size: 1.6cm; range: 0.5-3.7cm). Recurrent disease was detected in 3 of the 16 lesions treated with EtOH (mean size:
1.1cm; range: 0.5-1.5cm). One of these recurrences was successfully treated with RFA, two were successfully retreated with EtOH. Permanent vocal cord paralysis occurred following one RFA procedure of a lateral compartment supraclavicular node. Tg levels
were available for 9 of the 19 patients treated with neck ablation. In these patients, Tg levels decreased to or remained at undetectable or low detectable levels following ablation. Two of the 11 distant focal metastases recurred and were successfully
retreated with RFA, the remainder showed no sign of recurrence or disease progression at the treatment site at last follow-up (mean: 29.5 months; range: 7-60 months) and there were no treatment complications of distant focal lesions.<br><br>

CONCLUSION: Image-guided ablation is a safe and feasible treatment option for locally recurrent WTC following adequate surgery as well as for distant focal WTC metastases. Our results suggest that RFA is more effective than EtOH for local neck lesions despite being used to treat larger lesions.;T;@OI""/exhibits/RSNA2012ExtraCrani/;T{;{	;I"w<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific &#38; Educational Exhibits</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific &#38; Educational Exhibits</span></h1>
			<!-- title block :: end -->
 
<h3>Extracranial Tumors of the Head and Neck&#58; Palliative and Curative Roles for Image-Guided Ablation</h3>

<p class="mainContent_abstractData">
	Guenette JP, Monchik JM, Dupuy DE
	
	
	<br>Radiological Society of North America 98th Scientific Assembly and National Meeting
	<br>November 25-30, 2012, Chicago, IL
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/RSNA2012ExtraCrani375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	PURPOSE/AIM: To highlight the emerging role of image&#45;guided ablation in the treatment of extracranial head and neck tumors, with a focus on thyroid metastases, including a review of tumor and imaging characteristics, appropriate ablation modalities, and interesting cases.<br><br>

CONTENT ORGANIZATION: 1. Review of thyroid tumor epidemiology and relevant neck anatomyÕæ 2. Indications for ablation of thyroid
tumor metastasesÕæ 3. Description of thyroid tumor ablation modalities, procedures, potential complications, and followupÕæ 4. Single&#45;center thyroid ablation experience to dateÕæ 5. Brief history of non&#45;thyroid head and neck tumor ablationÕæ 6. Specific tumor and patient characteristics important when considering head and neck ablationÕæ 7. Pictorial review of interesting casesÕæ 8. Summary of presented material.<br><br>

SUMMARY: While the image&#45;guided ablation of extracranial head and neck tumors remains unorthodox, the ablation of thyroid cancer metastases has been shown to be safe, effective, and curative and published cases suggest a role for ablation in the palliation of other head and neck tumors. Diagnostic and interventional radiologists should be aware of the success of these therapeutic modalities so that patients may be properly identified, referred, and treated.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I""PURPOSE/AIM: To highlight the emerging role of image&#45;guided ablation in the treatment of extracranial head and neck tumors, with a focus on thyroid metastases, including a review of tumor and imaging characteristics, appropriate ablation modalities, and interesting cases.<br><br>

CONTENT ORGANIZATION: 1. Review of thyroid tumor epidemiology and relevant neck anatomyÕæ 2. Indications for ablation of thyroid
tumor metastasesÕæ 3. Description of thyroid tumor ablation modalities, procedures, potential complications, and followupÕæ 4. Single&#45;center thyroid ablation experience to dateÕæ 5. Brief history of non&#45;thyroid head and neck tumor ablationÕæ 6. Specific tumor and patient characteristics important when considering head and neck ablationÕæ 7. Pictorial review of interesting casesÕæ 8. Summary of presented material.<br><br>

SUMMARY: While the image&#45;guided ablation of extracranial head and neck tumors remains unorthodox, the ablation of thyroid cancer metastases has been shown to be safe, effective, and curative and published cases suggest a role for ablation in the palliation of other head and neck tumors. Diagnostic and interventional radiologists should be aware of the success of these therapeutic modalities so that patients may be properly identified, referred, and treated.;T;
I""PURPOSE/AIM: To highlight the emerging role of image&#45;guided ablation in the treatment of extracranial head and neck tumors, with a focus on thyroid metastases, including a review of tumor and imaging characteristics, appropriate ablation modalities, and interesting cases.<br><br>

CONTENT ORGANIZATION: 1. Review of thyroid tumor epidemiology and relevant neck anatomyÕæ 2. Indications for ablation of thyroid
tumor metastasesÕæ 3. Description of thyroid tumor ablation modalities, procedures, potential complications, and followupÕæ 4. Single&#45;center thyroid ablation experience to dateÕæ 5. Brief history of non&#45;thyroid head and neck tumor ablationÕæ 6. Specific tumor and patient characteristics important when considering head and neck ablationÕæ 7. Pictorial review of interesting casesÕæ 8. Summary of presented material.<br><br>

SUMMARY: While the image&#45;guided ablation of extracranial head and neck tumors remains unorthodox, the ablation of thyroid cancer metastases has been shown to be safe, effective, and curative and published cases suggest a role for ablation in the palliation of other head and neck tumors. Diagnostic and interventional radiologists should be aware of the success of these therapeutic modalities so that patients may be properly identified, referred, and treated.;T;@UI""/exhibits/RSNA2012Modalities/;T{;{	;I"ﬁ<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific &#38; Educational Exhibits</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific &#38; Educational Exhibits</span></h1>
			<!-- title block :: end -->
 
<h3>A Guide to Choosing the Best Thermal Ablation Modality When Treating Soft Tissue Tumors</h3>

<p class="mainContent_abstractData">
	Guenette JP, Mayo-Smith WW, Healey TT, Iannuccilli JD, Dupuy DE
	
	
	<br>Radiological Society of North America 98th Scientific Assembly and National Meeting
	<br>November 25-30, 2012, Chicago, IL
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/RSNA2012Modalities375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	PURPOSE/AIM: To provide a review of the relevant basic science and to share experience that will help interventional radiologists consistently choose the optimal thermal ablation modality.<br><br>

CONTENT ORGANIZATION: 1. Review of radiofrequency ablation, microwave ablation, and cryoablation biophysicsÕæ 2. Review of thermal ablation monitoring capabilitiesÕæ 3. Anatomic considerationsÕæ 4. Tumor characteristic considerationsÕæ 5. Treatment goal considerationsÕæ 6. Pictorial review of interesting and demonstrative casesÕæ 6. Summary of presented material.<br><br>

SUMMARY: Research has shown the safety and efficacy of radiofrequency ablation, microwave ablation, and cryoablation in the treatment of a wide variety of tumors, however studies comparing the modalities are limited, many tumors amenable to ablation are unusually located, and the effects of and ability to monitor each modality varies significantly. By properly considering modality biophysics and monitoring, tumor characteristics, surrounding anatomy, and treatment goals, the interventional radiologist will be able to optimize outcomes on an ablationbyablation basis.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"yPURPOSE/AIM: To provide a review of the relevant basic science and to share experience that will help interventional radiologists consistently choose the optimal thermal ablation modality.<br><br>

CONTENT ORGANIZATION: 1. Review of radiofrequency ablation, microwave ablation, and cryoablation biophysicsÕæ 2. Review of thermal ablation monitoring capabilitiesÕæ 3. Anatomic considerationsÕæ 4. Tumor characteristic considerationsÕæ 5. Treatment goal considerationsÕæ 6. Pictorial review of interesting and demonstrative casesÕæ 6. Summary of presented material.<br><br>

SUMMARY: Research has shown the safety and efficacy of radiofrequency ablation, microwave ablation, and cryoablation in the treatment of a wide variety of tumors, however studies comparing the modalities are limited, many tumors amenable to ablation are unusually located, and the effects of and ability to monitor each modality varies significantly. By properly considering modality biophysics and monitoring, tumor characteristics, surrounding anatomy, and treatment goals, the interventional radiologist will be able to optimize outcomes on an ablationbyablation basis.;T;
I"yPURPOSE/AIM: To provide a review of the relevant basic science and to share experience that will help interventional radiologists consistently choose the optimal thermal ablation modality.<br><br>

CONTENT ORGANIZATION: 1. Review of radiofrequency ablation, microwave ablation, and cryoablation biophysicsÕæ 2. Review of thermal ablation monitoring capabilitiesÕæ 3. Anatomic considerationsÕæ 4. Tumor characteristic considerationsÕæ 5. Treatment goal considerationsÕæ 6. Pictorial review of interesting and demonstrative casesÕæ 6. Summary of presented material.<br><br>

SUMMARY: Research has shown the safety and efficacy of radiofrequency ablation, microwave ablation, and cryoablation in the treatment of a wide variety of tumors, however studies comparing the modalities are limited, many tumors amenable to ablation are unusually located, and the effects of and ability to monitor each modality varies significantly. By properly considering modality biophysics and monitoring, tumor characteristics, surrounding anatomy, and treatment goals, the interventional radiologist will be able to optimize outcomes on an ablationbyablation basis.;T;@[I"%/largeimages/JVIR2013thyroid375/;T{;{ I"/publications/IGI2013Lung/;T{;{	;I"£<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Publications</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Publications</span></h1>
			<!-- title block :: end -->
 
<h3>Lung Ablation</h3>

<p class="mainContent_abstractData">
	Guenette JP, Dupuy DE in Mauro et. al., ed.
	<br>Image Guided Interventions 2/e
	
	
	
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/IGI2013Lung375.jpg" alt="Research-Related Image">
	Introduction:
</h4> 
<p>
	Image-guided thermal ablation is an increasingly studied and used treatment for both cure and palliation of primary and secondary lung cancer. The technique has been used for a little over a decade and has been proven safe and effective in treating a variety of solid tumors including many in the lung, liver, kidney, breast, bone, and adrenal gland. It may be used in conjunction with radiotherapy and systemic chemotherapy and is relatively low cost. Thermal ablation modalities include radiofrequency, microwave, laser, and cryotherapy. Randomized controlled clinical trials have not yet been conducted to establish efficacy of thermal ablation
alone, in combination with, or relative to other established treatments of lung neoplasms. However, an increasing number of single and multicenter cohort studies have consistently established the safety and suggest efficacy for medically inoperable disease. The remainder of this chapter highlights the basic biophysics underlying thermal ablation modalities, specifically within the unique anatomy and physiology of the lung, the understood safety and efficacy of thermal lung ablation given our experience to date, newly
introduced advances in thermal lung ablation techniques, and the current role of thermal ablation in the treatment of lung cancer.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"Image-guided thermal ablation is an increasingly studied and used treatment for both cure and palliation of primary and secondary lung cancer. The technique has been used for a little over a decade and has been proven safe and effective in treating a variety of solid tumors including many in the lung, liver, kidney, breast, bone, and adrenal gland. It may be used in conjunction with radiotherapy and systemic chemotherapy and is relatively low cost. Thermal ablation modalities include radiofrequency, microwave, laser, and cryotherapy. Randomized controlled clinical trials have not yet been conducted to establish efficacy of thermal ablation
alone, in combination with, or relative to other established treatments of lung neoplasms. However, an increasing number of single and multicenter cohort studies have consistently established the safety and suggest efficacy for medically inoperable disease. The remainder of this chapter highlights the basic biophysics underlying thermal ablation modalities, specifically within the unique anatomy and physiology of the lung, the understood safety and efficacy of thermal lung ablation given our experience to date, newly
introduced advances in thermal lung ablation techniques, and the current role of thermal ablation in the treatment of lung cancer.;T;
I"Image-guided thermal ablation is an increasingly studied and used treatment for both cure and palliation of primary and secondary lung cancer. The technique has been used for a little over a decade and has been proven safe and effective in treating a variety of solid tumors including many in the lung, liver, kidney, breast, bone, and adrenal gland. It may be used in conjunction with radiotherapy and systemic chemotherapy and is relatively low cost. Thermal ablation modalities include radiofrequency, microwave, laser, and cryotherapy. Randomized controlled clinical trials have not yet been conducted to establish efficacy of thermal ablation
alone, in combination with, or relative to other established treatments of lung neoplasms. However, an increasing number of single and multicenter cohort studies have consistently established the safety and suggest efficacy for medically inoperable disease. The remainder of this chapter highlights the basic biophysics underlying thermal ablation modalities, specifically within the unique anatomy and physiology of the lung, the understood safety and efficacy of thermal lung ablation given our experience to date, newly
introduced advances in thermal lung ablation techniques, and the current role of thermal ablation in the treatment of lung cancer.;T;@dI"%/publications/Radiology2013Bone/;T{;{	;I"A<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette :: Scientific Publications</title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle">&#47; Scientific Publications</span></h1>
			<!-- title block :: end -->
 
<h3>Solitary Painful Osseous Metastases&#58; Correlation of Imaging&#45;Features with Pain Palliation after Radiofrequency Ablation &#45; A Multicenter American College of Radiology Imaging Network Study</h3>

<p class="mainContent_abstractData">
	Guenette JP, Lopez MJ, Kim E, Dupuy DE
	<br>Radiology. In Press.
	
	
	
	
</p>

<h4>
	<img class="abstractImage" src="../largeimages/Radiology2013Bone375.jpg" alt="Research-Related Image">
	Abstract:
</h4> 
<p>
	PURPOSE: To identify the correlation of pre- and post-ablation imaging features with pain relief, pain intensity, and patient
mood after radiofrequency (RF) ablation of solitary painful osseous metastases.<br><br>

MATERIALS AND METHODS: This prospective, multicenter group trial was approved by each institutional review board. Participants were enrolled between November 1, 2001, and April 6, 2006. Written informed consent was obtained from all subjects, and patient confidentiality protocols were followed in compliance with HIPAA. Computed tomography (CT)-guided RF ablation and contrast‚Äìenhanced 1-month follow-up CT and/or magnetic resonance imaging were performed in 49 subjects (24 men, 25 women; age range, 34‚Äì83 years)
with a confi rmed malignant solitary bone lesion of maximum dimension &#8804; 8cm that was causing intractable pain. Pain intensity and patient mood were measured before and after RF ablation. Tumor imaging features were recorded. Unadjusted and adjusted linear mixed-effects models, with a random intercept for each subject, were used to model patient mood, pain relief, and pain intensity scores at three times after ablation as a function of each tumor characteristic.<br><br>

RESULTS: Decreased postablation tumor pain correlated with preablation tumor volume (P = .02) and pathologic fracture (P =
.01), while pain relief correlated with pathologic fracture (P = .03) and percentage of bone-tumor interface (BTI) ablated (P = .02). Conversely, presence of an irregular rim after ablation (P = .02) and rim thickness (P = .01) correlated with increased pain. There was no evidence in this study that RF ablation of increased tumor percentage or increased volume leads to better pain relief or decreased pain (P &#62; .05).<br><br>

CONCLUSION: Existing pathologic fracture and smaller tumor size appear to be predictive parameters of success when selecting
patients for palliative RF ablation of painful solitary osseous metastases. Successful palliation also appears to be related to the percentage of BTI ablated.
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I"PURPOSE: To identify the correlation of pre- and post-ablation imaging features with pain relief, pain intensity, and patient
mood after radiofrequency (RF) ablation of solitary painful osseous metastases.<br><br>

MATERIALS AND METHODS: This prospective, multicenter group trial was approved by each institutional review board. Participants were enrolled between November 1, 2001, and April 6, 2006. Written informed consent was obtained from all subjects, and patient confidentiality protocols were followed in compliance with HIPAA. Computed tomography (CT)-guided RF ablation and contrast‚Äìenhanced 1-month follow-up CT and/or magnetic resonance imaging were performed in 49 subjects (24 men, 25 women; age range, 34‚Äì83 years)
with a confi rmed malignant solitary bone lesion of maximum dimension &#8804; 8cm that was causing intractable pain. Pain intensity and patient mood were measured before and after RF ablation. Tumor imaging features were recorded. Unadjusted and adjusted linear mixed-effects models, with a random intercept for each subject, were used to model patient mood, pain relief, and pain intensity scores at three times after ablation as a function of each tumor characteristic.<br><br>

RESULTS: Decreased postablation tumor pain correlated with preablation tumor volume (P = .02) and pathologic fracture (P =
.01), while pain relief correlated with pathologic fracture (P = .03) and percentage of bone-tumor interface (BTI) ablated (P = .02). Conversely, presence of an irregular rim after ablation (P = .02) and rim thickness (P = .01) correlated with increased pain. There was no evidence in this study that RF ablation of increased tumor percentage or increased volume leads to better pain relief or decreased pain (P &#62; .05).<br><br>

CONCLUSION: Existing pathologic fracture and smaller tumor size appear to be predictive parameters of success when selecting
patients for palliative RF ablation of painful solitary osseous metastases. Successful palliation also appears to be related to the percentage of BTI ablated.;T;
I"PURPOSE: To identify the correlation of pre- and post-ablation imaging features with pain relief, pain intensity, and patient
mood after radiofrequency (RF) ablation of solitary painful osseous metastases.<br><br>

MATERIALS AND METHODS: This prospective, multicenter group trial was approved by each institutional review board. Participants were enrolled between November 1, 2001, and April 6, 2006. Written informed consent was obtained from all subjects, and patient confidentiality protocols were followed in compliance with HIPAA. Computed tomography (CT)-guided RF ablation and contrast‚Äìenhanced 1-month follow-up CT and/or magnetic resonance imaging were performed in 49 subjects (24 men, 25 women; age range, 34‚Äì83 years)
with a confi rmed malignant solitary bone lesion of maximum dimension &#8804; 8cm that was causing intractable pain. Pain intensity and patient mood were measured before and after RF ablation. Tumor imaging features were recorded. Unadjusted and adjusted linear mixed-effects models, with a random intercept for each subject, were used to model patient mood, pain relief, and pain intensity scores at three times after ablation as a function of each tumor characteristic.<br><br>

RESULTS: Decreased postablation tumor pain correlated with preablation tumor volume (P = .02) and pathologic fracture (P =
.01), while pain relief correlated with pathologic fracture (P = .03) and percentage of bone-tumor interface (BTI) ablated (P = .02). Conversely, presence of an irregular rim after ablation (P = .02) and rim thickness (P = .01) correlated with increased pain. There was no evidence in this study that RF ablation of increased tumor percentage or increased volume leads to better pain relief or decreased pain (P &#62; .05).<br><br>

CONCLUSION: Existing pathologic fracture and smaller tumor size appear to be predictive parameters of success when selecting
patients for palliative RF ablation of painful solitary osseous metastases. Successful palliation also appears to be related to the percentage of BTI ablated.;T;@jI"!/largeimages/IGI2013Lung375/;T{;{ I" /largeimages/JSO2010CHM375/;T{;{ I"'/largeimages/Radiology2013Bone375/;T{;{ I"%/largeimages/AAES2012Thyroid375/;T{;{ I"(/largeimages/RSNA2012ExtraCrani375/;T{;{ I"(/largeimages/RSNA2012Modalities375/;T{;{ I"/GuenetteJP_CV/;T{;{ I"/_header/;T{;{	;I"–<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8">
		<title>Jeffrey Guenette </title>
		<meta name="description" content="Jeffrey Guenette">
		<meta name="keywords" content="Jeffrey Guenette, Jeff Guenette">
		<meta name="author" content="Jeffrey P. Guenette">
    <link rel="stylesheet" href="/style.css">
    <meta name="generator" content="nanoc 3.6.3"> 
  </head>
  <body>
		<!-- container :: begin -->
		<div id="container">
 
			<!-- title block :: begin -->
			<h1>Jeffrey P. Guenette <span class="subtitle"></span></h1>
			<!-- title block :: end -->
 
<h3></h3>

<p class="mainContent_abstractData">
	
	
	
	
	
	
</p>

<h4>
	<img class="abstractImage" src="" alt="Research-Related Image">
	:
</h4> 
<p>
	
	
	<br><br><a href="../index.html">Return to Home Page</a>
</p>

<div class="clear"></div>
			
			<!-- footer :: begin -->
			<div class="footer">
				<a href="http://www.w3.org/html/logo/" target="w3c"><img src="http://www.w3.org/html/logo/badge/html5-badge-h-solo.png" 
					width="32" height="32" alt="HTML5 Powered with CSS3 / Styling, and Semantics"></a>&nbsp;
				<a href="http://jigsaw.w3.org/css-validator/check/referer" target="w3"><img style="border:0;width:88px;height:31px" 
					src="http://jigsaw.w3.org/css-validator/images/vcss" alt="Valid CSS!"></a>&nbsp;
				<img src="../ruby_logo.gif" alt="Ruby Programming Language" width="28" height="32">
			</div>
			<!-- footer :: end --> 
		
		</div>
		<!-- container :: end -->
  </body>
</html>

;T;	I" ;T;
I" ;T;@Ä:versioni